Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction/aims: Idiopathic inflammatory myopathies (IIMs) are classified into five subtypes that are associated with distinct groups of myositis-specific antibodies (MSAs). Variations in the prevalence, genetic predisposition and clinical manifestations exist in patients with IIM from different ethnic backgrounds. In this study, we aimed to characterize the immunopathological changes in muscle tissue and serum cytokines in a Vietnamese IIM cohort with Kinh ethnicity.

Methods: Muscle biopsies, sera, clinical data, and autoantibody profiles from 64 patients with IIM were included. Muscles were stained by immunohistochemistry using antibodies that target immune cells and molecules. Serum cytokines were measured by multiplex bead arrays. Clustering analysis was performed using the partitioning around medoids algorithm.

Results: The anti-MDA5 antibody was the most common MSA in this cohort (15.6%), followed by anti-Jo-1 (10.9%). A wide range of clinical manifestations and immunohistological features were seen within the serologically defined subgroups. There was no difference in the levels of immune cells, capillary density or dilation, or patterns of C5b-9 expression between the myositis subgroups. MHC-I patterns were the only immunomorphological variable that was different in these subgroups. IP-10, IL-17A, and APRIL were increased in patients with IIM compared to healthy controls (p = 5.7 × 10, 6.9 × 10, 2.4 × 10, respectively) but without difference between IIM subgroups.

Discussion: Vietnamese patients with IIM demonstrated widely varying clinical and immunopathological features, with dermatomyositis and immune-mediated necrotizing myopathy representing opposite ends of MHC-I upregulation in muscle tissue. Thus classification of myositis requires comprehensive evaluation of clinical manifestations, serology profiling and muscle pathology.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12338015PMC
http://dx.doi.org/10.1002/mus.28455DOI Listing

Publication Analysis

Top Keywords

patients iim
16
clinical manifestations
12
idiopathic inflammatory
8
inflammatory myopathies
8
muscle tissue
8
serum cytokines
8
immune cells
8
iim
6
clinical
5
immune characterization
4

Similar Publications

Therapeutics Update in Immune Mediated Rheumatic Diseases: Rheumatoid Arthritis, Idiopathic Inflammatory Myositis and ANCA Associated Vasculitis.

Clin Med (Lond)

September 2025

Rheumatology Research Group, Department of Inflammation and Ageing, College of Medicine & Health, University of Birmingham, Birmingham, UK.; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.

Immune-mediated inflammatory diseases (IMIDs) are a group of common clinically diverse conditions which are characterised by systemic inflammation. They often pose medical challenges due to their multi organ involvement, chronicity, associated co-morbidities and poor impact on quality of life to patients. The management for IMIDs has changed profoundly over the past twenty years with the paradigm of treatment shifting away from broad immunosuppression towards pathway specific targeted treatment.

View Article and Find Full Text PDF

Objective: To examine whether features of the B cell receptor (BCR) IgG repertoire correlate with disease activity and clinical phenotypes in systemic autoimmune diseases (SAIDs).

Methods: High-throughput sequencing was performed on IgG heavy chain repertoires from 138 patients with SAIDs, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), scleroderma (SSc), and idiopathic inflammatory myopathy (IIM), as well as 36 healthy controls (HC). We analyzed V/D/J gene usage, clonal distribution and diversity, CDR3 length distribution and amino acid usage, and the correlation between specific BCR features and clinical features.

View Article and Find Full Text PDF

Neutrophil extracellular traps mediate macrophage polarization and pyroptosis through the TLR9-NF-κB/AIM2 pathway exacerbating myositis-associated interstitial lung disease.

Int Immunopharmacol

September 2025

Department of Cuiying Biomedical Research Center, Lanzhou University Second Hospital, Lanzhou, China; Department of Rheumatology, Lanzhou University Second Hospital, Lanzhou, China; Gansu Province Clinical Research Center for Rheumatology, Lanzhou, Gansu, China. Electronic address:

Background: Previous studies by our research group have demonstrated that neutrophil extracellular traps (NETs) play a pathogenic role in myositis-associated interstitial lung disease (IIM-ILD). Based on this, we hypothesized that NETs may contribute to the pathogenesis of IIM-ILD by regulating macrophage polarization and pyroptosis.

Methods: Pathological studies were conducted using lung biopsy samples from a dermatomyositis-associated interstitial lung disease (DM-ILD) patient and lung tissues from experimental autoimmune myositis (EAM) mice.

View Article and Find Full Text PDF

Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin (hf-SCIg) for inflammatory myositis: a multicenter retrospective real-world observational study.

Eur J Intern Med

August 2025

Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy; Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Melbourne, Australia. Electronic address:

Background: Subcutaneous immunoglobulin (SCIg) is a promising alternative to intravenous Ig (IVIg) for the treatment of idiopathic inflammatory myositis (IIM), thanks to its more favorable safety profile, reduced costs, and lower impact on patients' quality of life. We assessed the short- and long-term effectiveness and safety of recombinant human hyaluronidase-facilitated SCIg (hf-SCIg) in patients with IIM treated at different referral centers in Italy.

Methods: A multicenter, retrospective, real-life cohort study was conducted on consecutive adult patients diagnosed with IIM according to the EULAR/ACR criteria, treated with hf-SCIg for remission induction or maintenance.

View Article and Find Full Text PDF

A possible role for immunogenetic factors in myositis developing after vaccination in the pre-covid-19 era.

Front Immunol

September 2025

Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, United States.

Introduction: Vaccinations have had a transformative impact on public health, reducing the incidence of many infectious diseases and increasing survival. However, there remains uncertainty about the potential of vaccines to trigger autoimmune diseases such as the idiopathic inflammatory myopathies (IIM). Myositis after vaccination (MAV) is a rare clinical entity, but given immunogenetic associations with other adverse events, we explored genetic risk factors, particularly human leukocyte antigen (HLA) alleles and GM/KM immunoglobulin allotypes, that may predispose individuals to develop MAV.

View Article and Find Full Text PDF